Literature DB >> 29663409

Are We Ready to Include Organ-Impaired Patients in Oncology Trials? A Clinical Pharmacology Perspective on Recent Recommendations.

Joanna C Masters1,2, Peter H Wiernik1,3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29663409     DOI： 10.1002/jcph.1127

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  5 in total

Review 1.  Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

Authors:  Morgan A Casal; Thomas D Nolin; Jan H Beumer
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-19       Impact factor: 8.237

2.  Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.

Authors:  Ahmed Hamed Salem; Nimita Dave; Thomas Marbury; Beibei Hu; Dale Miles; Suresh K Agarwal; Orlando F Bueno; Rajeev M Menon
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 3.  Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.

Authors:  Arun Radhakrishnan; Gowthamarajan Kuppusamy; Sivasankaran Ponnusankar; Nikhitha K Shanmukhan
Journal:  Pharmacogenomics J       Date:  2019-12-10       Impact factor: 3.550

4.  Precision dosing to avoid adverse drug reactions.

Authors:  Thomas M Polasek; Carl M J Kirkpatrick; Amin Rostami-Hodjegan
Journal:  Ther Adv Drug Saf       Date:  2019-12-11

5.  Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds.

Authors:  Mohamed Elmeliegy; Derek Z Yang; Engie Salama; Kourosh Parivar; Diane D Wang
Journal:  J Clin Pharmacol       Date:  2020-07-20       Impact factor: 3.126
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.